Effects of orlistat, alone or combined with hypolipidemic drugs, on cardiovascular risk factors

Future Lipidology

Volumn 4, Issue 3, 2009, Pages 331-341

  Filippatos, T D ^a   Derdemezis, C S ^a   Elisaf, M S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Cholesterol; Glucose; High density lipoprotein; Low density lipoprotein; Obesity; Orlistat; Triglycerides; Uric acid; Weight loss

Indexed keywords

ADIPOCYTOKINE; ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; CERIVASTATIN; CHYLOMICRON; EZETIMIBE; FATTY ACID; FENOFIBRATE; FLUINDOSTATIN; GAMMA GLUTAMYLTRANSFERASE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPROSTANE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PHOSPHOLIPASE A2; PHYTOSTEROL; PLACEBO; SIMVASTATIN; SOMATOMEDIN; STANOL ESTER; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; URIC ACID;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIET THERAPY; DRUG EFFICACY; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPID ABSORPTION; LIPOPROTEIN METABOLISM; MONOTHERAPY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

EID: 67249098263     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/CLP.09.25     Document Type: Review

References (95)

1. Kiortsis DN, Filippatos TD, Elisaf MS: The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabetes Metab. 31, 15-22 (2005).
2. Sjostrom L, Rissanen A, Andersen T et al.: Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 352, 167-172 (1998).
3. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR: Orlistat in the long-term treatment of obesity in primary care settings. Arch. Fam. Med. 9, 160-167 (2000).
4. Rucker D, Padwal R, Li SK, Curioni C, Lau DC: Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 335, 1194-1199 (2007).
5. Davidson MH, Hauptman J, DiGirolamo M et al.: Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 281,235-242 (1999).
6. Van Gaal LF, Broom JI, Enzi G, Toplak H: Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group. Eur. J. Clin. Pharmacol. 54, 125-132 (1998).
7. Zhi J, Melia AT, Eggers H, Joly R, Patel IH: Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J. Clin. Pharmacol. 35, 1103-1108 (1995).
8. Filippatos TD, Derdemezis CS, Gazi IF et al.: Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf. 31, 53-65 (2008).
9. Ballinger A, Peikin SR: Orlistat: its current status as an anti-obesity drug. Eur. J. Pharmacol. 440, 109-117 (2002).
10. Baigent C, Keech A, Kearney PM et al.: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366, 1267-1278 (2005).
11. Lewington S, Whitlock G, Clarke R et al.: Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370, 1829-1839 (2007).
12. Teng B, Thompson GR, Sniderman AD et al.: Composition and distribution of low density lipoprotein fractions in hyper-apobetalipoproteinemia, normolipidemia, and familial hypercholesterolemia. Proc. Natl Acad. Sci. USA 80, 6662-6666 (1983).
13. Gazi IF, Tsimihodimos V, Tselepis AD, Elisaf M, Mikhailidis DP: Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin. Biol. Ther. 7, 53-72 (2007).
14. Broom I, Wilding J, Stott P, Myers N: Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study. Int. J. Clin. Pract. 56, 494-499 (2002).
15. Hill JO, Hauptman J, Anderson JW et al.: Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am. J. Clin. Nutr. 69, 1108-1116 (1999).
16. Gokcel A, Gumurdulu Y, Karakose H et al.: Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes. Metab. 4, 49-55 (2002).
17. Lindgarde F: The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J. Intern. Med. 248, 245-254 (2000).
18. Bakris G, Calhoun D, Egan B et al.: Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J. Hypertens. 20, 2257-2267 (2002).
19. Muls E, Kolanowski J, Scheen A, Van Gaal L: The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int. J. Obes. Relat. Metab. Disord. 25, 1713-1721 (2001).
20. Micic D, Ivkovic-Lazar T, Dragojevic R et al.: Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia. Med. Pregl. 52, 323-333 (1999).
21. Lucas CP, Boldrin MN, Reaven GM: Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia. Am. J. Cardiol. 91, 961-964 (2003).
22. Reaven G, Segal K, Hauptman J, Boldrin M, Lucas C: Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. Am. J. Cardiol. 87, 827-831 (2001).
23. Bray G, Torgerson J, Sjostrom L, Boldrin M, Hauptman J: Effect of orlistat in obese patients with the metabolic syndrome as defined by the NCEP (ATP III). Diabetes 52(1), A392 (2003).
24. Hollander PA, Elbein SC, Hirsch IB et al.: Role of orlistat in the treatment of obese patients with Type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 21, 1288-1294 (1998).
25. Miles JM, Leiter L, Hollander P et al.: Effect of orlistat in overweight and obese patients with Type 2 diabetes treated with metformin. Diabetes Care 25, 1123-1128 (2002).
26. Kelley DE, Bray GA, Pi-Sunyer FX et al.: Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated Type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 25, 1033-1041 (2002).
27. Reitsma JB, Castro Cabezas M, de Bruin TW, Erkelens DW: Relationship between improved postprandial lipemia and low-density lipoprotein metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor. Metabolism 43, 293-298 (1994).
28. Mittendorfer B, Ostlund RE Jr, Patterson BW, Klein S: Orlistat inhibits dietary cholesterol absorption. Obes. Res. 9, 599-604 (2001).
29. Nakou ES, Filippatos TD, Kiortsis DN et al.: The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia. Expert Opin. Pharmacother. 9, 3151-3158 (2008).
30. Filippatos TD, Liberopoulos EN, Kostapanos M et al.: The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-β1-HDL levels in obese patients with metabolic syndrome. Diabetes Obes. Metab. 10, 476-483 (2008).
31. McBride P: Triglycerides and risk for coronary artery disease. Curr. Atheroscler. Rep. 10, 386-390 (2008).
32. Rubins HB, Robins SJ, Collins D et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 341, 410-418 (1999).
33. Tan KC, Tso AW, Tam SC, Pang RW, Lam KS: Acute effect of orlistat on post-prandial lipaemia and free fatty acids in overweight patients with Type 2 diabetes mellitus. Diabet. Med. 19, 944-948 (2002).
34. Tzotzas T, Krassas GE, Bruckert E: Administration of orlistat in a patient with familial hyperchylomicronemia. Atherosclerosis 165, 185-186 (2002).
35. Petrogiannopoulos C, Kalogeropoulos S, Latsios GS et al.: Orlistat use in overweight women with mild hypercholesterolemia. Int J. Clin. Pharmacol. Res 22, 85-88 (2002).
36. Derosa G, Mugellini A, Ciccarelli L, Fogari R: Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. Clin. Ther. 25, 1107-1122 (2003).
37. Tzotzas T, Samara M, Constantinidis T, Tziomalos K, Krassas G: Short-term administration of orlistat reduced daytime triglyceridemia in obese women with the metabolic syndrome. Angiology 58, 26-33 (2007).
38. Filippatos T, Tsimihodimos V, Kostapanos M et al.: Analysis of the 6-month effect of orlistat, alone or in combination with fenofibrate, administration on triglyceride-rich lipoprotein metabolism in overweight and obese patients with metabolic syndrome. J. Clin. Lipidol. 2, 279-284 (2008).
39. Hausenloy DJ, Yellon DM: Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Heart 94, 706-714 (2008).
40. Briel M, Ferreira-Gonzalez I, You JJ et al.: Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 338, b92 (2009).
41. Kontush A, Chapman MJ: Antiatherogenic small, dense HDL - guardian angel of the arterial wall? Nat. Clin. Pract. Cardiovasc. Med. 3, 144-153 (2006).
42. Poobalan A, Aucott L, Smith WC et al.: Effects of weight loss in overweight/obese individuals and long-term lipid outcomes - a systematic review. Obes. Rev. 5, 43-50 (2004).
43. Sartorio A, Lafortuna CL, Vangeli V et al.: Short-term changes of cardiovascular risk factors after a non-pharmacological body weight reduction program. Eur. J. Clin. Nutr. 55, 865-869 (2001).
44. Noakes M, Keogh JB, Foster PR, Clifton PM: Effect of an energy-restricted, high-protein, low-fat diet relative to a conventional high-carbohydrate, low-fat diet on weight loss, body composition, nutritional status, and markers of cardiovascular health in obese women. Am. J. Clin. Nutr. 81, 1298-1306 (2005).
45. Filippatos TD, Gazi IF, Liberopoulos EN et al.: The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis 193, 428-437 (2007).
46. Filippatos TD, Kiortsis DN, Liberopoulos EN et al.: Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr. Med. Res. Opin. 21, 1997-2006 (2005).
47. Tonstad S, Pometta D, Erkelens DW et al.: The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur. J. Clin. Pharmacol. 46, 405-410 (1994).
48. Halpern A, Mancini MC, Suplicy H et al.: Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. Diabetes Obes. Metab. 5, 180-188 (2003).
49. Hanefeld M, Sachse G: The effects of orlistat on body weight and glycaemic control in overweight patients with Type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes. Metab. 4, 415-423 (2002).
50. Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G: Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes. Res. 8, 49-61 (2000).
51. von Eckardstein A, Nofer JR, Assmann G: High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 21, 13-27 (2001).
52. Danielsen EM, Hansen GH, Poulsen MD: Apical secretion of apolipoproteins from enterocytes. J. Cell Biol. 120, 1347-1356 (1993).
53. Al Majali K, Cooper MB, Staels B et al.: The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients. Diabetologia 49, 527-537 (2006).
54. Heymsfield SB, Segal KR, Hauptman J et al.: Effects of weight loss with orlistat on glucose tolerance and progression to Type 2 diabetes in obese adults. Arch. Intern. Med. 160, 1321-1326 (2000).
55. Tong PC, Lee ZS, Sea MM et al.: The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without Type 2 diabetes. Arch. Intern. Med. 162, 2428-2435 (2002).
56. Dimitrov D, Bohchelian H, Koeva L: Effect of orlistat on plasma leptin levels and risk factors for the metabolic syndrome. Metab. Syndr. Relat. Disord. 3, 122-129 (2005).
57. Rosenfalck AM, Hendel H, Rasmussen MH et al.: Minor long-term changes in weight have beneficial effects on insulin sensitivity and β-cell function in obese subjects. Diabetes Obes. Metab. 4, 19-28 (2002).
58. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L: XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of Type 2 diabetes in obese patients. Diabetes Care 27, 155-161 (2004).
59. Richelsen B, Tonstad S, Rossner S et al.: Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study. Diabetes Care 30, 27-32 (2007).
60. Jacob S, Rabbia M, Meier MK, Hauptman J: Orlistat 120 mg improves glycaemic control in Type 2 diabetic patients with or without concurrent weight loss. Diabetes Obes. Metab. 11 (4),361-371 (2009).
61. Metwally M, Amer S, Li TC, Ledger WL: An RCT of metformin versus orlistat for the management of obese anovulatory women. Hum. Reprod. 24 (4), 966-975 (2008).
62. Athyros VG, Elisaf M, Papageorgiou AA et al.: Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am. J. Kidney Dis. 43, 589-599 (2004).
63. Kim DJ, Noh JH, Cho NH et al.: Serum γ-glutamyltransferase within its normal concentration range is related to the presence of diabetes and cardiovascular risk factors. Diabet. Med. 22, 1134-1140 (2005).
64. Lee DS, Evans JC, Robins SJ et al.: γ-glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler. Thromb. Vasc. Biol. 27, 127-133 (2007).
65. Assy N, Hussein O, Abassi Z: Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis. Gut 56, 443-444 (2007).
66. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA: Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 49, 80-86 (2009).
67. Bougoulia M, Triantos A, Koliakos G: Effect of weight loss with or without orlistat treatment on adipocytokines, inflammation, and oxidative markers in obese women. Hormones (Athens) 5, 259-269 (2006).
68. Samuelsson L, Gottsater A, Lindgarde F: Decreasing levels of tumour necrosis factor α and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors. Diabetes Obes. Metab. 5, 195-201 (2003).
69. Gallistl S, Sudi KM, Cvirn G, Muntean W, Borkenstein M: Effects of short-term energy restriction and physical training on haemostatic risk factors for coronary heart disease in obese children and adolescents. Int. J. Obes. Relat. Metab. Disord. 25, 529-532 (2001).
70. Rissanen P, Vahtera E, Krusius T, Uusitupa M, Rissanen A: Weight change and blood coagulability and fibrinolysis in healthy obese women. Int. J. Obes. Relat. Metab. Disord. 25, 212-218 (2001).
71. Tselepis AD, Chapman JM: Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler. Curr. Vasc. Pharmacol. 3, 57-68 (2002).
72. Tselepis AD, Dentan C, Karabina SA, Chapman MJ, Ninio E: PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler. Thromb. Vasc. Biol. 15, 1764-1773 (1995).
73. Nambi V, Hoogeveen RC, Chambless L et al.: Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study. Stroke 40, 376-381 (2009).
74. Packard CJ, O'Reilly DS, Caslake MJ et al.: Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 343, 1148-1155 (2000).
75. Ballantyne? CM, Hoogeveen RC, Bang H et al.: Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 109, 837-842 (2004).
76. Koenig W, Khuseyinova N, Lowel H, Trischler G, Meisinger C: Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 110, 1903-1908 (2004).
77. Oei HH, van der Meer IM, Hofman A et al.: Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 111, 570-575 (2005).
78. Elisaf M, Tselepis AD: Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis. Biochem. Pharmacol. 66, 2069-2073 (2003).
79. Nakou ES, Filippatos TD, Georgoula M et al.: The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr. Med. Res. Opin. 24, 1919-1929 (2008).
80. Tzotzas T, Filippatos TD, Triantos A et al.: Effects of a low-calorie diet associated with weight loss on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in healthy obese women. Nutr. Metab. Cardiovasc. Dis. 18, 477-482 (2008).
81. Gazi I, Lourida ES, Filippatos T et al.: Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin. Chem. 51, 2264-2273 (2005).
82. Tsimihodimos V, Karabina SA, Tambaki AP et al.: Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler. Thromb. Vasc. Biol. 22, 306-311 (2002).
83. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA: Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr. Opin. Lipidol. 7, 69-76 (1996).
84. Mackness MI, Mackness B, Durrington PN: Paraoxonase and coronary heart disease. Atheroscler. Curr. Vasc. Pharmacol. 3, 49-55 (2002).
85. Mackness MI, Arrol S, Abbott C, Durrington PN: Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 104, 129-135 (1993).
86. Audikovszky M, Pados G, Seres I et al.: Orlistat increases serum paraoxonase activity in obese patients. Nutr. Metab. Cardiovasc. Dis. 17, 268-273 (2007).
87. Sahin M, Tanaci N, Yucel M et al.: Acute effects of orlistat on postprandial serum leptin levels in nondiabetic obese patients. Minerva Endocrinol. 33, 169-173 (2008).
88. Dixon AN, Valsamakis G, Hanif MW et al.: Effect of the orlistat on serum endotoxin lipopolysaccharide and adipocytokines in South Asian individuals with impaired glucose tolerance. Int. J. Clin. Pract. 62, 1124-1129 (2008).
89. Filippatos T, Randeva H, Derdemezis C, Elisaf M, Mikhailidis D: Visfatin/ pbef and atherosclerosis-related diseases. Curr. Vasc. Pharmacol. (2009) (In press).
90. Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T: Association between plasma visfatin and vascular endothelial function in patients with Type 2 diabetes mellitus. Metabolism 56, 451-458 (2007).
91. Filippatos TD, Derdemezis CS, Kiortsis DN, Tselepis AD, Elisaf MS: Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. J. Endocrinol. Invest. 30, 323-326 (2007).
92. Filippatos TD, Derdemezis CS, Georgoula M et al.: Fenofibrate and orlistat, alone or in combination, do not alter plasma visfatin levels in subjects with metabolic syndrome. J. Med. Sci. Res. 2,9-10 (2007).
93. Derosa G, Mugellini A, Ciccarelli L, Rinaldi A, Fogari R: Effects of orlistat, simvastatin and orlistat + simvastatin in obese patients with hypercholesterolemia: a randomised, open-label trial. Curr. Ther. Res. Clin. Exp. 63, 621-633 (2002).
94. Derosa G, Mugellini A, Fogari R: Comparison between diet, orlistat and cerivastatin in hypercholesterolemic, obese patients, with mild hypertension (Abstract). Atheroscler. Curr. Vasc. Pharmacol. 2, 93 (2001).
95. Tolentino MC, Ferenczi A, Ronen L, Poretsky L: Combination of gemfibrozil and orlistat for treatment of combined hyperlipidemia with predominant hypertriglyceridemia. Endocr. Pract. 8, 208-212 (2002).